General Information of MET (ID: META00149)
Name Dopamine
Synonyms   Click to Show/Hide Synonyms of This Metabolite
2-(3,4-Dihydroxyphenyl)ethylamine; 3,4 Dihydroxyphenethylamine; 3,4-Dihydroxyphenethylamine; 3,4-Dihydroxyphenylethylamine; 3-Hydroxytyramine; 4-(2-Aminoethyl)-1,2-benzenediol; 4-(2-Aminoethyl)-pyrocatechol; 4-(2-Aminoethyl)benzene-1,2-diol; 4-(2-Aminoethyl)catechol; 4-(2-Aminoethyl)pyrocatechol; Deoxyepinephrine; Dopamin; Dopamina; Dopamine hydrochloride; Dopaminum; Dopastat; Dophamine; Dynatra; Hydrochloride, dopamine; Hydroxytyramin; Hydroxytyramine; Intropin; Medopa; Oxytyramine; Revivan; a-(3,4-Dihydroxyphenyl)-b-aminoethane; alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
Source Endogenous;Escherichia Coli Metabolite;Food;Carcinogenic Potency;Drug;Toxins/Pollutant;Cosmetic;TCM Ingredients;Microbial
Structure Type   Benzenediols  (Click to Show/Hide the Complete Structure Type Hierarchy)
Benzenoids
Phenols
Benzenediols
PubChem CID
681
HMDB ID
HMDB0000073
Formula
C8H11NO2
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=681"></iframe>
3D MOL 2D MOL
  Click to Show/Hide the Molecular/Functional Data (External Links/Property/Function) of This Metabolite
KEGG ID
C03758
DrugBank ID
DB00988
ChEBI ID
18243
FooDB ID
FDB012163
ChemSpider ID
661
METLIN ID
64
Physicochemical Properties Molecular Weight 153.18 Topological Polar Surface Area 66.5
XlogP -1 Complexity 119
Heavy Atom Count 11 Rotatable Bond Count 2
Hydrogen Bond Donor Count 3 Hydrogen Bond Acceptor Count 3
Function
Dopamine is a member of the catecholamine family of neurotransmitters in the brain and is a precursor to epinephrine (adrenaline) and norepinephrine (noradrenaline). Dopamine is synthesized in the body (mainly by nervous tissue and adrenal glands) first by the hydration of the amino acid tyrosine to DOPA by tyrosine hydroxylase and then by the decarboxylation of DOPA by aromatic-L-amino-acid decarboxylase. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (dopamine receptors) mediates its action, which plays a major role in reward-motivated behaviour. Dopamine has many other functions outside the brain. In blood vessels, dopamine inhibits norepinephrine release and acts as a vasodilator (at normal concentrations); in the kidneys, it increases sodium excretion and urine output; in the pancreas, it reduces insulin production; in the digestive system, it reduces gastrointestinal motility and protects intestinal mucosa; and in the immune system, it reduces the activity of lymphocytes. Parkinson's disease, a degenerative condition causing tremor and motor impairment, is caused by a loss of dopamine-secreting neurons in an area of the midbrain called the substantia nigra. There is evidence that schizophrenia involves altered levels of dopamine activity, and most antipsychotic drugs used to treat this are dopamine antagonists, which reduce dopamine activity. Attention deficit hyperactivity disorder, bipolar disorder, and addiction are also characterized by defects in dopamine production or metabolism. It has been suggested that animals derived their dopamine-synthesizing machinery from bacteria via horizontal gene transfer that may have occurred relatively late in evolutionary time. This is perhaps a result of the symbiotic incorporation of bacteria into eukaryotic cells that gave rise to mitochondria. Dopamine is elevated in the urine of people who consume bananas. When present in sufficiently high levels, dopamine can be a neurotoxin and a metabotoxin. A neurotoxin is a compound that disrupts or attacks neural tissue. A metabotoxin is an endogenously produced metabolite that causes adverse health effects at chronically high levels. Chronically high levels of dopamine are associated with neuroblastoma, Costello syndrome, leukemia, phaeochromocytoma, aromatic L-amino acid decarboxylase deficiency, and Menkes disease (MNK). High levels of dopamine can lead to hyperactivity, insomnia, agitation and anxiety, depression, delusions, excessive salivation, nausea, and digestive problems. A study has shown that urinary dopamine is produced by Bacillus and Serratia
Regulatory Network
Full List of Protein(s) Regulating This Metabolite
      Equilibrative nucleoside transporter (ENT)
            Solute carrier family 29 member 4 (SLC29A4) Click to Show/Hide the Full List of Regulating Pair(s):   2 Pair(s)
               Detailed Information Protein   Info click to show the details of this protein
               Regulating Pair (1) Experim Info click to show the details of experiment for validating this pair [1]
                      Introduced Variation Mutation (138T) of SLC29A4
                      Induced Change Dopamine concentration: decrease
                      Summary Introduced Variation         Induced Change 
                      Disease Status Asperger syndrome [ICD-11: 6A02]
                      Details It is reported that mutation (138T) of SLC29A4 leads to the decrease of dopamine levels compared with control group.
               Regulating Pair (2) Experim Info click to show the details of experiment for validating this pair [1]
                      Introduced Variation Mutation (D326E) of SLC29A4
                      Induced Change Dopamine concentration: decrease
                      Summary Introduced Variation         Induced Change 
                      Disease Status Asperger syndrome [ICD-11: 6A02]
                      Details It is reported that mutation (D326E) of SLC29A4 leads to the decrease of dopamine levels compared with control group.
      GPCR glutamate (GPCR-3)
            Glutamate receptor mGLU2 (mGluR2) Click to Show/Hide the Full List of Regulating Pair(s):   1 Pair(s)
               Detailed Information Protein   Info click to show the details of this protein
               Regulating Pair Experim Info click to show the details of experiment for validating this pair [2]
                      Introduced Variation Knockout of Grm2
                      Induced Change Dopamine concentration: decrease (FC = 0.75)
                      Summary Introduced Variation         Induced Change 
                      Disease Status Healthy individual
                      Details It is reported that knockout of mGlu2/3 leads to the decrease of dopamine levels compared with control group.
            Glutamate receptor mGLU3 (mGluR3) Click to Show/Hide the Full List of Regulating Pair(s):   1 Pair(s)
               Detailed Information Protein   Info click to show the details of this protein
               Regulating Pair Experim Info click to show the details of experiment for validating this pair [2]
                      Introduced Variation Knockout of Grm3
                      Induced Change Dopamine concentration: decrease (FC = 0.75)
                      Summary Introduced Variation         Induced Change 
                      Disease Status Healthy individual
                      Details It is reported that knockout of mGlu2/3 leads to the decrease of dopamine levels compared with control group.
      GPCR rhodopsin (GPCR-1)
            Dopamine D4 receptor (D4R) Click to Show/Hide the Full List of Regulating Pair(s):   1 Pair(s)
               Detailed Information Protein   Info click to show the details of this protein
               Regulating Pair Experim Info click to show the details of experiment for validating this pair [3]
                      Introduced Variation Knockout of Drd4
                      Induced Change Dopamine concentration: decrease (FC = 0.28)
                      Summary Introduced Variation         Induced Change 
                      Disease Status Healthy individual
                      Details It is reported that knockout of DRD4 leads to the decrease of dopamine levels compared with control group.
      Pore-forming PNC peptide (PNC)
            Cellular tumor antigen p53 (TP53) Click to Show/Hide the Full List of Regulating Pair(s):   1 Pair(s)
               Detailed Information Protein   Info click to show the details of this protein
               Regulating Pair Experim Info click to show the details of experiment for validating this pair [4]
                      Introduced Variation Knockout of TP53
                      Induced Change Dopamine concentration: decrease (Log2 FC=0.8)
                      Summary Introduced Variation         Induced Change 
                      Disease Status Colon cancer [ICD-11: 2B90]
                      Details It is reported that knockout of TP53 leads to the decrease of dopamine levels compared with control group.
References
1 Autism spectrum disorder associated with low serotonin in CSF and mutations in the SLC29A4 plasma membrane monoamine transporter (PMAT) gene. Mol Autism. 2014 Aug 13;5:43.
2 Decreased striatal dopamine in group II metabotropic glutamate receptor (mGlu2/mGlu3) double knockout mice. BMC Neurosci. 2013 Sep 22;14:102.
3 Dopamine D4 receptor knockout mice exhibit neurochemical changes consistent with decreased dopamine release. J Neurosci Methods. 2007 Nov 30;166(2):306-14.
4 Integrative omics analysis of p53-dependent regulation of metabolism. FEBS Lett. 2018 Feb;592(3):380-393.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.